drugset / Trial / NCT06773130
HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of HRS-4642 combined with Nimotuzumab in patients with recurrent or metastatic pancreatic ductal adenocarcinoma.
Timeline
- Start
- 2025-02-10
- Primary completion
- 2026-08
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HRS-4642 | Unknown | 800 mg | — |
| Subject | HRS-4642 | Unknown | 1000 mg | — |
| Subject | HRS-4642 | Unknown | 1200 mg | — |
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | Intravenous |